Studies have revealed that cancers typically contain tens to hundreds of mutations, which often differ between patients. While the prospect of targeting this huge diversity of mutations via pharmacological approaches is daunting, immune-based treatments may offer a practical alternative owing to the enormous repertoire of antigen receptors expressed by the immune system. The results of this project provide the first evidence that peptides derived from common lymphoma mutations can elicit T-cell responses in the majority of healthy donors. The project team is currently completing the work plan by assessing whether T cell clones can recognize and destroy EZH2 mutant lymphoma cell lines. This will provide important preclinical data for therapeutic vaccine-based clinical trials for lymphoma. The equipment funded by this grant (ELISPOT reader and Guava cell analysis system) has greatly enhanced the biomedical research infrastructure in Victoria, and is greatly facilitating a wide variety of projects at the Deeley Research Centre (BCCA-DRC). The project team has been successful in obtaining a total of $1.5M funding for five new projects, enabled by the platform funded by SOF132.